Critical Outcome Technologies Selected to Present at Multiple Investor Conferences in New York City

Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT),
the bioinformatics and accelerated drug discovery company, will be a featured
presenter at two upcoming microcap investor conferences in New York City. The
Company will also be presenting at a dinner being held by the Financial
Investment Analysts of New York on the evening of May 27th. In addition to
providing a Company overview at all three events, President and CEO Dr. Wayne
Danter's presentation will highlight the Company's lead cancer drug candidate,
COTI-2, the opportunity to do R&D collaborations with CHEMSAS(R), and CHEMFirm,
the Company's small molecule profiling and investment due diligence tool.


On Wednesday, May 28th, Dr. Danter will present at SeeThruEquity's Microcap
Investor Conference being held at Convene Grand Central in Manhattan. Dr.
Danter's presentation is scheduled to begin at 2:30 p.m. EDT. 


On Thursday, May 29th, Dr. Danter will present at the third annual Marcum
Microcap Conference being held at the Grand Hyatt Hotel in Manhattan. Dr.
Danter's presentation is scheduled to begin at 10:00 a.m. EDT and will be
available via a live webcast. To access the webcast, go to
http://wsw.com/webcast/marcum2/cot.v. 


"These important presentations provide the Company with multiple high impact
opportunities to continue raising our profile with more potential life science
investors and customers in the United States," commented Dr. Danter. 


Dr. Danter will also be participating in one-on-one meetings with potential
investors and customers, and other interested parties who are registered to
attend these conferences.


About Critical Outcome Technologies Inc. 

COTI is a leading-edge bioinformatics company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI'S proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective.


For more information, visit www.criticaloutcome.com. 

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
[e-mail]


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
[e-mail]